2023 World Conference on Lung Cancer (Posters)-P2.07. Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO)

P2.07. Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO) - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents a study that aimed to investigate the impact of different genomic subtypes of EGFR-mutant non-small cell lung cancer (NSCLC) on the response to immunotherapy (IO) using real-world data. The study utilized the Flatiron Health-Foundation Medicine clinicogenomic database, which includes data from approximately 280 US cancer clinics. The dataset included 8,368 NSCLC cases with comprehensive genomic profiling and information on PD-L1 expression, tumor mutational burden (TMB), and patient histories.<br /><br />The results showed that patients with uncommon EGFR mutations, such as G719X, L861Q, and S768I, were more likely to have a smoking history compared to wild-type (WT) EGFR cases. PD-L1 expression varied among different EGFR subtypes, with Exon 19 and L858R tumors having lower percentages of PD-L1 positivity compared to WT. Uncommon mutations, on the other hand, had the highest percentage of high TMB.<br /><br />The study also evaluated the progression-free survival (rwPFS) with single-agent IO for each EGFR subtype compared to WT. The results showed that rwPFS was significantly shorter for all EGFR cases compared to WT. Additionally, all subtypes of EGFR had inferior rwPFS and a lower percentage of progression-free at 12 months compared to WT, including uncommon mutations.<br /><br />The study concludes that while uncommon EGFR mutations may have a more immunogenic profile, this does not translate into longer rwPFS with IO. Further research is needed to overcome IO resistance in EGFR-mutant NSCLC.<br /><br />In summary, this study provides insights into the genomic subtypes of EGFR-mutant NSCLC and their response to IO. It highlights the importance of considering the specific EGFR subtype in determining the effectiveness of immunotherapy for patients with NSCLC.

Asset Subtitle

Joseph Bodor

Meta Tag

Speaker Joseph Bodor

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

genomic subtypes

EGFR-mutant non-small cell lung cancer

immunotherapy

real-world data

Flatiron Health-Foundation Medicine

clinicogenomic database

PD-L1 expression

tumor mutational burden

progression-free survival

IO resistance